DeepPsy

DeepPsy operates at the intersection of mental-health diagnostics, clinical decision support, and medical software. Its differentiation is the combination of resting EEG and ECG analysis with a physician-facing report designed specifically for depression treatment selection. This places it closer to precision-psychiatry and biomarker companies than to general telehealth platforms, symptom-tracking applications, or standalone neurotechnology hardware vendors. The company’s offering also extends beyond analytics: DeepPsy coordinates recordings, manages secure submissions, performs quality checks, and delivers reports through a clinical workflow. Relative to broad digital mental-health providers, DeepPsy has a narrower and more clinically specialized proposition centered on treatment-response information. Its market position remains difficult to size because public information on customers, revenue, funding, and validation studies is limited.

DeepPsy’s trajectory shows a progression from biomarker research toward an integrated clinical service. The company has defined two complementary products: DeepPsy Biomarkers Report, which analyzes EEG and ECG recordings for psychiatric treatment planning, and DeepPsy Portal, which supports secure data submission, referral coordination, and reporting workflows. This combination suggests an effort to move beyond a standalone algorithm and embed the technology into routine clinical operations. Hiring activity across neurosciences, psychiatry, data science, and engineering is consistent with continued development of both the clinical evidence base and the software infrastructure. However, the available profile contains no founded date, employee count, funding history, product-launch dates, customer metrics, or disclosed clinical milestones. There is also no reported layoff activity. As a result, the company’s growth can be characterized by product and capability expansion rather than quantified commercial scale. The main potential inflection point is the operationalization of EEG- and ECG-derived insights for treatment selection across clinics and healthcare centers, but adoption and outcome data are not publicly established here.